stockportfolio.pro
Stocks / INSM vs WST
INSM vs WST
Insmed Incorporated and West Pharmaceutical Services, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
WST is the larger company ($22.9B vs $20.9B). On the fundamentals, INSM grows revenue faster (29.8% vs 7.4%); WST earns a higher net margin (16.1% vs -210.5%); WST has the stronger return on equity (15.5% vs -172.8%). Full numbers below — the stronger figure on each row is in green.
| Insmed Incorporated (INSM) | West Pharmaceutical Services, Inc. (WST) | |
|---|---|---|
| Market cap | $20.9B | $22.9B |
| Revenue (latest FY) | $606.42M | $3.07B |
| Net income (latest FY) | $-1.28B | $493.70M |
| Revenue growth (5y CAGR) | 29.8% | 7.4% |
| Net margin | -210.5% | 16.1% |
| Return on equity | -172.8% | 15.5% |
| P/E ratio | — | 43.3 |
| Dividend yield | — | 0.3% |
| Profitable years (of last 10) | 0 | 10 |
| Positive free cash flow | No | Yes |
Compare with another company:
See the full INSM vs WST breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open INSM's full financials → Open WST's full financials →More comparisons
Frequently asked questions
Which is bigger, INSM or WST?
West Pharmaceutical Services, Inc. is larger by market capitalization — $22.9B versus $20.9B.
Which grows faster, INSM or WST?
Over the last five fiscal years, Insmed Incorporated grew revenue faster — 29.8%/yr versus 7.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.